Stroke Recovery

Overview

Stroke recovery is one of the most compelling applications for peptide neuroscience. Semax has regulatory approval in Russia specifically for ischemic stroke treatment. The acute phase (first 10-14 days) represents the critical window when neuroprotective and neuroplastic interventions have the greatest impact. Peptides reduce penumbral damage, promote neuroplasticity, improve cerebral blood flow, and support the cellular machinery of repair and remyelination.

Recommended Peptides

Semax – Russian-approved for stroke; rapidly increases BDNF, VEGF, and tissue plasminogen activator activity; reduces infarct size in acute phase; improves neurological deficits and cognitive recovery; intranasal delivery for rapid CNS access; high-frequency dosing in acute phase (3-4 drops per nostril, 4-6 times daily)
BPC-157 – crosses blood-brain barrier; reduces neuroinflammation, protects neurons in the penumbra, accelerates nerve fiber regeneration; injectable for maximum bioavailability
TB-500 – promotes angiogenesis in ischemic brain tissue and neuronal repair; systemic administration distributes to brain
Cerebrolysin – approved in many countries for stroke rehabilitation; multi-component neuropeptide mixture promoting neuroplasticity, reducing apoptosis, and improving functional outcomes in clinical trials

Protocols

Related Conditions

Research Summary

Semax activates neurotrophin transcription (BDNF, NGF, TrkB) after cerebral ischemia in preclinical models (PMID-19633950), with genome-wide analysis showing immunomodulatory and vascular gene changes (PMID-24661604). BPC-157 demonstrates neuroprotective effects in stroke models via NO-system modulation (PMID-34380875). Clinical data for peptide stroke therapy remains limited.

#condition #neurological